Provider-guided programs
What does a peptide subscription actually cost?
Expect three separate cost layers: membership dues ($99–$299/month at Biohacker Network, offset by $99–$400 in monthly store credit), clinical services (consultation and labs, billed by the independent provider), and medication, priced and charged by the licensed pharmacy only if a prescription is appropriate. Any program that bundles all three into one number is hiding something.
Why we list costs separately
Bundled "all-inclusive" peptide pricing usually obscures either the clinical review or the medication economics. Separating the layers keeps the prescription decision independent from marketing and lets you compare programs honestly.
Layer 1: membership dues
Network $99/month, Pro $199/month, Elite $299/month (June 2025), each returning $99, $250, or $400 in monthly store credit plus 20–40% member discounts. Dues cover education, tools, community, expert sessions at higher tiers, and Network Points. Dues never purchase medication.
Layer 2: clinical services
Eligibility questionnaires, provider consultations, and laboratory work are billed by the independent licensed provider. Prices vary by state and provider; they are always disclosed before you commit.
Layer 3: medication
If — and only if — a provider determines therapy is appropriate, the licensed pharmacy sets and charges medication pricing. Compounded and FDA-approved products differ substantially in both price and risk profile.
How store credit and Network Points affect cost
Every renewal grants your tier’s monthly store credit ($99, $250, or $400) for eligible purchases, plus Network Points at your tier’s rate — 500, 1,000, or 2,000 per renewal. Points redeem at 100 points per $1 of eligible benefit value (1,000-point minimum, $50 per-order maximum) against dues, courses, and approved non-prescription benefits — reducing your effective membership cost without ever touching medication decisions.
References
- US Food and Drug Administration (2024). FDA's concerns with unapproved GLP-1 drugs used for weight loss. FDA Drug Alerts and Statements. SourceAgency notice
- US Food and Drug Administration (2023). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA Human Drug Compounding. SourceAgency notice
- US Food and Drug Administration (2023). Human drug compounding: compounded drugs are not FDA-approved. FDA. SourceAgency guidance
Found an error? Report a correction.